関: olopatadine hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/11/28 02:27:53」(JST)

wiki en

Olopatadine hydrochloride is an antihistamine (as well as anticholinergic and mast cell stabilizer), sold as a prescription eye drop (0.2% solution, Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as Patanol (or Opatanol in some countries). A decongestant nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008.^[1] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.^[2]

It should not be used to treat irritation caused by contact lenses. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.

There is potential for Olopatadine as a treatment modality for steroid rebound (red skin syndrome.) ^[3]

Olopatadine was developed by Kyowa Hakko Kogyo.^[4]

Side Effects

Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

Synthesis

Olopatadine synthesis:^[5]

References

^ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
^ Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). Retrieved 2008-08-10.
^ Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.".
^ Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd. Retrieved 16 September 2010.
^ Ueno, K.; Kubo, S.; Tagawa, H.; Yoshioka, T.; Tsukada, W.; Tsubokawa, M.; Kojima, H.; Kasahara, A. (1976). "6,11-Dihydro-11-oxodibenz[b,e]oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry 19 (7): 941. doi:10.1021/jm00229a017. edit

External links

Pataday website
Patanase website
Olopatadine Ophthalmic via MedlinePlus

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. アレルギー性結膜炎：マネージメント allergic conjunctivitis management
2. 春季カタル vernal keratoconjunctivitis
3. アレルギー性鼻炎の薬物療法 pharmacotherapy of allergic rhinitis
4. アトピー性角結膜炎 atopic keratoconjunctivitis
5. 慢性非アレルギー性鼻炎 chronic nonallergic rhinitis

English Journal

Chromatographic analysis of olopatadine in hydrophilic interaction liquid chromatography.

Maksić J1, Jovanović M2, Rakić T2, Popović I3, Ivanović D2, Jančić-Stojanović B4.
Journal of chromatographic science.J Chromatogr Sci.2015 May;53(5):680-6. doi: 10.1093/chromsci/bmu102. Epub 2014 Oct 9.
In this paper, chromatographic analysis of active substance olopatadine hydrochloride, which is used in eye drops as antihistaminic agent, and its impurity E isomer by hydrophilic interaction liquid chromatography (HILIC) and application of design of experiments (DoE) methodology are presented. In a
PMID 25300592

Antihistaminic drug olopatadine downmodulates T cell chemotaxis toward CCL17 in patients with atopic dermatitis.

Ito T1, Tatsuno K2, Sakabe J2, Fujiyama T2, Tokura Y2.
Allergology international : official journal of the Japanese Society of Allergology.Allergol Int.2015 Apr;64(2):200-2. doi: 10.1016/j.alit.2014.10.008. Epub 2015 Jan 2.
PMID 25838101

Refractory case of adrenergic urticaria successfully treated with clotiazepam.

Kawakami Y1, Gokita M, Fukunaga A, Nishigori C.
The Journal of dermatology.J Dermatol.2015 Mar 21. doi: 10.1111/1346-8138.12855. [Epub ahead of print]
Adrenergic urticaria (AU) is a rare type of stress-induced physical urticaria characterized by widespread pruritic urticarial papules. Diagnosis can be made by i.d. injection of adrenaline or noradrenaline, which produces the characteristic rash. Although the lesions of AU typically respond to beta-
PMID 25810001

Japanese Journal

イネ科花粉飛散時期のアレルギー性鼻炎患者におけるオロパタジン塩酸塩(アレロック)の治療効果と夜間睡眠障害・日常生活への影響

鈴木祐輔,太田伸男,高橋裕一 [他]
アレルギ-・免疫 18(11), 1692-1699, 2011-11
NAID 40019033830

治療オロパタジン塩酸塩の小児アトピー性皮膚炎に対する二重盲検比較試験

川島眞,中川秀己
西日本皮膚科 73(3), 278-289, 2011-06
NAID 40018897232

「オロパタジン」

Olopatadine
Systematic (IUPAC) name
	{(11Z)-11-[3-(dimethylamino)propylidene]-6,11-; dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
Clinical data
Trade names	Patanol and others
AHFS/Drugs.com	monograph
MedlinePlus	a602025
Pregnancy cat.	C;
Legal status	?
Routes	Ophthalmic, intranasal, oral
Pharmacokinetic data
Half-life	3 hours
Identifiers
CAS number	113806-05-6
ATC code	S01GX09 R01AC08
PubChem	CID 5281071
DrugBank	DB00768
ChemSpider	4444528
UNII	D27V6190PM
KEGG	D08293
ChEMBL	CHEMBL1189432
Chemical data
Formula	C21H23NO3
Mol. mass	337.412 g/mol
	SMILES O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3;
	InChI InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- ; Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N ;
(what is this?) (verify)

　　[★]

英: olopatadine
化: 塩酸オロパタジン olopatadine hydrochloride
商: アレロック、パタノール
関: 眼科用剤

[1] Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms

[KYOWA08-2] Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). Retrieved 2008-08-10.

[3] Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.".

[4] Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd. Retrieved 16 September 2010.

[5] Ueno, K.; Kubo, S.; Tagawa, H.; Yoshioka, T.; Tsukada, W.; Tsubokawa, M.; Kojima, H.; Kasahara, A. (1976). "6,11-Dihydro-11-oxodibenz[b,e]oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry 19 (7): 941. doi:10.1021/jm00229a017. edit

匿名

検索

案内

案内

olopatadine